134 related articles for article (PubMed ID: 32478706)
41. Central Nervous System Manifestations Associated with COVID-19.
Divani AA; Andalib S; Biller J; Di Napoli M; Moghimi N; Rubinos CA; Nobleza CO; Sylaja PN; Toledano M; Lattanzi S; McCullough LD; Cruz-Flores S; Torbey M; Azarpazhooh MR
Curr Neurol Neurosci Rep; 2020 Oct; 20(12):60. PubMed ID: 33128130
[TBL] [Abstract][Full Text] [Related]
42. Neurological manifestations of COVID-19: a review of what we know so far.
Gklinos P
J Neurol; 2020 Sep; 267(9):2485-2489. PubMed ID: 32458197
[TBL] [Abstract][Full Text] [Related]
43. Neurological consequences of COVID-19: what have we learned and where do we go from here?
Jarrahi A; Ahluwalia M; Khodadadi H; da Silva Lopes Salles E; Kolhe R; Hess DC; Vale F; Kumar M; Baban B; Vaibhav K; Dhandapani KM
J Neuroinflammation; 2020 Sep; 17(1):286. PubMed ID: 32998763
[TBL] [Abstract][Full Text] [Related]
44. SARS-CoV2 entry and spread in the lymphatic drainage system of the brain.
Bostancıklıoğlu M
Brain Behav Immun; 2020 Jul; 87():122-123. PubMed ID: 32360606
[No Abstract] [Full Text] [Related]
45. Practical recommendations for the management of diabetes in patients with COVID-19.
Bornstein SR; Rubino F; Khunti K; Mingrone G; Hopkins D; Birkenfeld AL; Boehm B; Amiel S; Holt RI; Skyler JS; DeVries JH; Renard E; Eckel RH; Zimmet P; Alberti KG; Vidal J; Geloneze B; Chan JC; Ji L; Ludwig B
Lancet Diabetes Endocrinol; 2020 Jun; 8(6):546-550. PubMed ID: 32334646
[TBL] [Abstract][Full Text] [Related]
46. The potential role of microvascular pathology in the neurological manifestations of coronavirus infection.
MacLean MA; Kamintsky L; Leck ED; Friedman A
Fluids Barriers CNS; 2020 Sep; 17(1):55. PubMed ID: 32912226
[TBL] [Abstract][Full Text] [Related]
47. Comment on "Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2)".
Chen S; Lu H; Liu Z; Yuan W
J Med Virol; 2020 Sep; 92(9):1399-1400. PubMed ID: 32383264
[No Abstract] [Full Text] [Related]
48. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.
Ghafouri-Fard S; Noroozi R; Vafaee R; Branicki W; Poṡpiech E; Pyrc K; Łabaj PP; Omrani MD; Taheri M; Sanak M
Biomed Pharmacother; 2020 Aug; 128():110296. PubMed ID: 32480226
[TBL] [Abstract][Full Text] [Related]
49. Cellular senescence as a potential mediator of COVID-19 severity in the elderly.
Nehme J; Borghesan M; Mackedenski S; Bird TG; Demaria M
Aging Cell; 2020 Oct; 19(10):e13237. PubMed ID: 32955770
[TBL] [Abstract][Full Text] [Related]
50. Neuroimaging in Zoonotic Outbreaks Affecting the Central Nervous System: Are We Fighting the Last War?
Goh GX; Tan K; Ang BSP; Wang LF; Tchoyoson Lim CC
AJNR Am J Neuroradiol; 2020 Oct; 41(10):1760-1767. PubMed ID: 32819907
[TBL] [Abstract][Full Text] [Related]
51. Acute neuromuscular syndromes with respiratory failure during COVID-19 pandemic: Where we stand and challenges ahead.
Galassi G; Marchioni A
J Clin Neurosci; 2022 Jul; 101():264-275. PubMed ID: 35660960
[TBL] [Abstract][Full Text] [Related]
52. Neurological Complications of SARS-CoV, MERS-CoV, and COVID-19.
Alshebri MS; Alshouimi RA; Alhumidi HA; Alshaya AI
SN Compr Clin Med; 2020; 2(11):2037-2047. PubMed ID: 33083695
[TBL] [Abstract][Full Text] [Related]
53. The potential impact of Covid-19 on CNS and psychiatric sequels.
Dehghani A; Zokaei E; Kahani SM; Alavinejad E; Dehghani M; Meftahi GH; Afarinesh MR
Asian J Psychiatr; 2022 Jun; 72():103097. PubMed ID: 35405524
[TBL] [Abstract][Full Text] [Related]
54. Disease Severity and Durability of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Response: A View Through the Lens of the Second Year of the Pandemic.
Pirofski LA
Clin Infect Dis; 2021 Sep; 73(6):e1345-e1347. PubMed ID: 33905478
[No Abstract] [Full Text] [Related]
55. The Role of ACE2 Receptors of the Olfactory System in Anosmia in COVID-19: An Overview.
Nasr MJ; Alizadeh Khatir A; Babazadeh A; Ebrahimpour S
Neurol Res Int; 2021; 2021():5776801. PubMed ID: 34777862
[TBL] [Abstract][Full Text] [Related]
56. Nitric oxide's physiologic effects and potential as a therapeutic agent against COVID-19.
Ricciardolo FLM; Bertolini F; Carriero V; Högman M
J Breath Res; 2020 Dec; 15(1):014001. PubMed ID: 33080582
[TBL] [Abstract][Full Text] [Related]
57. Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?
Pejic N; Stojkovic Lalosevic M; Stulic M; Culafic M; Culafic D
J Infect Dev Ctries; 2022 Sep; 16(9):1530-1532. PubMed ID: 36223632
[TBL] [Abstract][Full Text] [Related]
58. Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge.
Meyer-Frießem CH; Gierthmühlen J; Baron R; Sommer C; Üçeyler N; Enax-Krumova EK
Pain Rep; 2021; 6(1):e893. PubMed ID: 33490851
[TBL] [Abstract][Full Text] [Related]
59. [Central Nervous System and Psychiatric Complications in Long Coronavirus Disease 2019].
Hagiya H; Otsuka F
No Shinkei Geka; 2022 Sep; 50(5):1071-1077. PubMed ID: 36128823
[TBL] [Abstract][Full Text] [Related]
60. Challenging Cases in Neurology: Neurologic Complications of COVID-19.
Horta L; Bakhtyari A; Greige T; Anand P
Semin Neurol; 2022 Dec; 42(6):708-715. PubMed ID: 36417991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
